Smruthi Organics Ltd (540686) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 540686 | NSE: | Pharmaceuticals & Drugs | Small Cap

Smruthi Organics Share Price

124.80 3.10 2.55%
as on 16-Dec'25 16:59

DeciZen - make an informed investing decision on Smruthi Organics

Based on:

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Smruthi Organics stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
30.56
Market Cap:
142.9 Cr.
52-wk low:
103
52-wk high:
169

Is Smruthi Organics Ltd an attractive stock to invest in?

1. Is Smruthi Organics Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Smruthi Organics Ltd is a average quality company.

2. Is Smruthi Organics Ltd undervalued or overvalued?

The key valuation ratios of Smruthi Organics Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Smruthi Organics Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Smruthi Organics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Smruthi Organics:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Smruthi Organics Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 9.5%10.6%-1%21.5%25%39.1%21%7.4%8.2%8%-
Value Creation
Index
-0.3-0.2-1.10.50.81.80.5-0.5-0.4-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 73.879.497.3137131127133141128126120
Sales YoY Gr.-7.6%22.7%41.2%-4.6%-3.5%5.4%5.8%-9.5%-1.3%-
Adj EPS 0.61.4-2.865.314.99.23.73.33.14.1
YoY Gr.-126.2%-303.6%NA-12.3%183.5%-38%-60.1%-11.9%-4.6%-
BVPS (₹) 26.828.225.431.837.152.958.759.660.862.661.9
Adj Net
Profit
0.71.6-3.26.9617.110.64.23.73.65
Cash Flow from Ops. 149.25.112.121.422.82.212.14.410-
Debt/CF from Ops. 2.63.562.30.70.41.30.52.71.7-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 6.1%-0.8%-1.9%-1.3%
Adj EPS 19.8%-10%-30.5%-4.6%
BVPS9.9%11%2.2%2.9%
Share Price - -1.6% -11.4% -0.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
2.35-10.52115.333.116.66.25.456.6
Op. Profit
Mgn %
14.412.63.412.512.122.61479.59.711.7
Net Profit
Mgn %
12-3.354.613.57.932.92.83.9
Debt to
Equity
1.211.10.80.40.200.10.20.20.1
Working Cap
Days
31725819415516313913215319720472
Cash Conv.
Cycle
99908066584881929911939

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 6.60%

Sales growth has been subdued in last 3 years -1.87%

Net Profit has been subdued in last 3 years -30.51%

Sales growth is not so good in last 4 quarters at 1.57%

Latest Financials - Smruthi Organics Ltd.

Standalone Consolidated
TTM EPS (₹) 4.1 -
TTM Sales (₹ Cr.) 120 -
BVPS (₹.) 61.9 -
Reserves (₹ Cr.) 59 -
P/BV 2.02 -
PE 30.56 -
From the Market
52 Week Low / High (₹) 103.00 / 169.00
All Time Low / High (₹) 21.70 / 419.35
Market Cap (₹ Cr.) 143
Equity (₹ Cr.) 11.5
Face Value (₹) 10
Industry PE 40.2

Management X-Ray of Smruthi Organics:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Smruthi Organics - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Smruthi Organics

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales747997137131127133141128126
Operating Expenses 63699412111698115131116114
Manufacturing Costs891113141216181922
Material Costs43496191836680917269
Employee Cost 78913141214161717
Other Costs 53134585676
Operating Profit 1110317152918101212
Operating Profit Margin (%) 14.4%12.5%3.3%12.1%11.6%22.6%13.8%6.9%9.4%9.7%
Other Income 0101411000
Interest 5444311112
Depreciation 4444444566
Exceptional Items 0000000000
Profit Before Tax 23-510122414455
Tax 11-13473011
Profit After Tax 12-3781710444
PAT Margin (%) 1.0%2.0%-3.3%5.0%6.4%13.5%7.8%2.9%2.8%2.8%
Adjusted EPS (₹)0.61.4-2.86.07.415.09.13.63.13.1
Dividend Payout Ratio (%)0%0%0%11%14%20%33%55%48%48%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 31322936426067687072
Share Capital 444441111111111
Reserves 27282533394956575860
Minority Interest0000000000
Debt312729281610351014
Long Term Debt14862210168
Short Term Debt1719232514103546
Trade Payables15172230221411252916
Others Liabilities 26104777791111
Total Liabilities 1028584101889288107119113

Fixed Assets

Gross Block88309498104107114122131141
Accumulated Depreciation5606468727681859196
Net Fixed Assets 32303030323133374045
CWIP 1112011213
Investments 0000000000
Inventories19192123171820243028
Trade Receivables19212536252128374132
Cash Equivalents 22244161211
Others Assets 2912561144564
Total Assets 1028584101889288107119113

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 1495122123212410
PBT 23-510122414555
Adjustment 8777745567
Changes in Working Capital 4-13-550-133-6-0
Tax Paid 0-0-00-3-6-4-1-1-2
Cash Flow From Investing Activity 0-0-3-4-5-37-10-7-11
Capex -1-2-4-5-5-4-7-9-8-12
Net Investments 00000013-110
Others 1110011000
Cash Flow From Financing Activity -14-9-2-5-17-7-12-231
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -4-4-2-4-0-0-0164
Interest Paid -5-4-4-4-3-1-1-1-1-2
Dividend Paid 0000-20-3-3-2-2
Others -5042-12-5-72-11
Net Cash Flow -0002-113-30-0-0

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)2.415.03-10.4820.9721.4333.2316.276.115.215.04
ROCE (%)9.5310.6-0.9621.542539.08217.398.227.98
Asset Turnover Ratio0.750.911.161.491.391.411.491.461.171.09
PAT to CFO Conversion(x)144.5N/A1.712.631.350.2312.5
Working Capital Days
Receivable Days9586868285666884108106
Inventory Days86837558555152577483
Payable Days130117114104114995771134119

Smruthi Organics Ltd Stock News

Smruthi Organics Ltd FAQs

The current trading price of Smruthi Organics on 16-Dec-2025 16:59 is ₹124.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 15-Dec-2025 the market cap of Smruthi Organics stood at ₹142.8.
The latest P/E ratio of Smruthi Organics as of 15-Dec-2025 is 30.56.
The latest P/B ratio of Smruthi Organics as of 15-Dec-2025 is 2.02.
The 52-week high of Smruthi Organics is ₹169.0 and the 52-week low is ₹103.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Smruthi Organics is ₹119.9 ( Cr.) .

About Smruthi Organics Ltd

Smruthi Organics Ltd is a mid-size, public limited, API manufacturing company from Solapur, India. Smruthi Organics Ltd was established in1989 by qualified technocrats and has very good experience and reputation in the pharmaceutical industry for the supply of quality products. 

Their core competency is multi-step organic synthesis and large scale manufacturing of organic molecules. Their focus has always been API for the regulated markets. They have been part of successful contract manufacturing and custom synthesis agreements with leading European, American and Japanese customers. They are currently expanding our R&D to become a one-stop solution provider from concept to execution for all API including, but not restricted to, the following: 
  • Process Development
  • Process Optimization
  • Process Validation
  • Analytical Methods Validation
  • Regulatory Support and DMF Registrations
  • Commercial Manufacturing

Their constant endeavor to improve operations and systems has contributed to our growth. they encourage operational transparency with customers, which complements to confidence building for stronger relationships. Customer satisfaction is their highest priority and they constantly strive on optimizing delivery times of all their services.

Smruthi Organics Ltd facility is USFDA approved and European GMP certified for Carbidopa, Metformin HCL and Norfloxacin. It has successfully filed 4 European and US drug master files for different products.

Smruthi can manage a potential molecule's entire development life cycle up to commercialization through rigorous planning and proper execution. Smruthi can independently or in conjunction with the customer develop optimized synthesis process, perform scale-up and process validations, compile DMF and provide the customer with regulatory support for finished formulation dossier registration. The engagement can be either on an FTE or deliverables basis. We respect absolute confidentiality in such sensitive relationships enhancing smooth exchange of information.

Product range of the company includes:

API   
  • Amlodipine Base
  • Amlodipine Besilate
  • Carbidopa
  • Carvedilol
  • Chlorhexidine Base
  • Chlorhexidine Salts
  • Ciprofloxacin HCI
  • Clofibrate
  • Diloxanide Furoate
  • Enrofloxacin
  • Fenofibrate
  • Fluconazole
  • Iopomidol
  • Metformin HCI
  • Norfloxacin
  • Pefloxacin
  • S-Amlodipine
  • Nabumetone
Drug Intermediate
  • Nabumetone
  • Iopamidol / Iohexol
  • Montelukast
  • Iopamidol
  • Co-enzyme Q10
  • Atorvastatin
  • Carvedilol
  • Ciprofloxacin/Enrofloxacin
  • Perindopril
Achievements/ recognition:
  • The company’s quality systems and facilities are approved by USFDA, EU – GMP and ISO 9001:2000. 

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×